ClinicalTrials.gg
RecruitingNCT07223437REVASC-PADUpdated Nov 4, 2026

REVASC-PAD: REstricted VASCular Exercise for Peripheral Arterial Disease - A Feasibility Study at University of Tennessee Medical Center

An interventional study of Blood Flow Restriction Cuff System and Low-load Resistance Training in Peripheral Arterial Disease, sponsored by University of Tennessee Graduate School of Medicine. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-04.

Sponsored by University of Tennessee Graduate School of Medicine · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Apr 2026; still recruiting 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
81
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 479 studies in Peripheral Arterial Disease with a site in United States — 82 open to participants now, 101 under way, 10 of them phase 3. Peripheral Arterial Disease · United States.

Planned enrollment
164th of 373
81 · median 64
Started
2026
with 14 others
No phase
217 of 479
40 open now
Primary completion
2027-04
later than 45 of 100 live
Registered
461st of 479
by date

Among the 479 studies in Peripheral Arterial Disease with a site in United States, this one is the 164th largest by planned enrollment of the 373 interventional ones that give a count, is one of 15 that started in 2026, is one of 217 with no phase, reaches primary completion later than 45 of the 100 other live ones, and was the 461st registered.

Peripheral Arterial Disease

1,378 studies on the registry are indexed under Peripheral Arterial Disease; 276 are open to participants now.

Browse Peripheral Arterial Disease studies →

Open to participants now

82 of the 479 studies in Peripheral Arterial Disease with a site in United States are open now. Recruiting first, the newest first:

76 more — sign in →

All 82 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 193 Peripheral Arterial Disease studies recruiting now, 139 (72%) set no upper age limit and 9 (5%) stop at 75 or younger; 13 take children under 18; 19 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 479 studies in Peripheral Arterial Disease with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the effects of Blood Flow Restriction (BFR) training on walking function, health-related quality of life, and safety among adults with Peripheral Arterial Disease (PAD).

The main aims of the study are:

  1. Evaluate change in walking function among patients with PAD undergoing BFR training. The investigators will assess change in Six-Minute Walk Test (6MWT) distance from baseline to post-intervention and 3-month follow-up to compare functional improvements between the BFR group and the two control groups
  2. Assess changes in health-related quality of life among patients with PAD undergoing BFR training. The investigators will use the EuroQol 5-Dimension 5-Level (EQ-5D-5L) scale to evaluate quality-of-life changes from baseline to post-intervention and 3-month follow-up across all study arms
  3. Evaluate the safety and feasibility of a supervised BFR training program for patients with PAD. The investigators will compare adverse event (AE) and serious adverse event (SAE) rates across study arms, while also monitoring sessional ratings of perceived exertion (RPE), dyspnea, and claudication pain as indicators of symptom response and exercise tolerance. Feasibility will be assessed through enrollment success, intervention adherence, and retention rates across groups
03

Conditions studied

  • Peripheral Arterial Disease
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. 18 years of age or older
  2. Diagnosed peripheral arterial disease with stable claudication (symptomatic presentation unchanged for 6 months)
  3. Ankle-brachial index (ABI) between 0.4 and 0.9.
  4. Eligible referral to cardiovascular or pulmonary rehabilitation
  5. Prior revascularization permitted if symptoms are stable and other criteria are met

Exclusion criteria

Exclusion Criteria:

  1. Recent change in resting suggesting significant ischemia, recent myocardial infarction (within 2 weeks), or another acute cardiac event
  2. Unstable angina
  3. Uncontrolled cardiac arrhythmias
  4. Symptomatic severe aortic stenosis or other significant valvular disease
  5. Decompensated symptomatic heart failure
  6. Acute pulmonary embolism or infarction
  7. Acute noncardiac disorder likely to interfere with or be worsened by exercise (e.g., infection, thyrotoxicosis)
  8. Acute myocarditis or pericarditis
  9. Acute thrombophlebitis
  10. Physical disability precluding safe or adequate exercise performance
  11. Significant electrolyte abnormalities
  12. tachyarrhythmias or bradyarrhythmias
  13. High-degree atrioventricular block
  14. Atrial fibrillation with uncontrolled ventricular response
  15. Hypertrophic obstructive cardiomyopathy with resting left ventricular outflow gradient of >25 mmHg
  16. Known active aortic dissection
  17. Severe resting arterial hypertension (SBP>200mmHg or DBP >110 mmHg)
  18. Mental impairment preventing cooperation with study procedures
  19. Current pregnancy
  20. Moderate to severe peripheral neuropathy
  21. Open wounds or compromised skin near BFR cuff site
  22. Active DVT or thromboembolic event within the past year
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
81 participants (estimated)

Study arms

  • Experimental
    Blood Flow Restriction (BFR) Training

    Participants perform supervised lower-body resistance training using pneumatic cuffs (Smart Cuff Pro or equivalent) applied to the proximal thighs. Cuffs are inflated to 60-80% of the participant's measured arterial occlusion pressure (AOP). Pressure is increased at Weeks 5 and 9 based on tolerance. Cuff inflation will not exceed 80% of limb occlusion pressure. Cuffs will be immediately deflated if participants' vitals suggest poor tolerance.

    Behavioral: Blood Flow Restriction Cuff System

  • Active comparator
    Low-Load Traditional Resistance Training (LL-RT)

    Participants perform the same two calf exercises (seated and standing calf raises) without BFR cuffs. If participants demonstrate the ability to complete all prescribed repetitions without undue strain, planned load progressions of approximately 5-10% 1RM will be introduced at Weeks 5 and 9. Repetitions and sets will remain fixed to match the BFR protocol.

    Behavioral: Low-load Resistance Training

  • Active comparator
    High-Load Traditional Resistance Training (HL-RT)

    Participants in this group will perform seated and standing calf raises following a more conventional strength training model. Similar to the other groups, if participants can complete their prescribed workload without excessive strain, two planned load progressions (5-10% 1RM) will be applied at Weeks 5 and 9. Repetitions and sets will remain fixed to preserve consistency in training structure across groups. This group serves as a benchmark for conventional resistance training in clinical and musculoskeletal rehabilitation populations.

    Behavioral: High-load Resistance Training

Interventions

  • BehavioralBlood Flow Restriction Cuff System

    All BFR resistance sessions will include two standardized lower-extremity exercises: seated calf raises and standing calf raises. Each session will follow this protocol: 1. 1 set of 30 repetitions, followed by 3 sets of 15 repetitions 2. 30 seconds rest between sets, with the cuff remaining inflated 3. Load set at 20-35% of 1RM 4. Cuff deflated immediately after the fourth set or after 6 continuous minutes of inflation, whichever comes first

  • BehavioralLow-load Resistance Training

    Two resistance exercises (seated and standing calf raises) using the same repetition structure 1. 1 set of 30 repetitions, followed by 3 sets of 15 repetitions 2. Load set at 20-35% of 1RM 3. 30 seconds rest between sets 4. No BFR cuffs will be used

  • BehavioralHigh-load Resistance Training

    Each session includes: 1. 3 sets of 8-12 repetitions 2. Load set at 60-70% of 1RM 3. Rest periods of 60-90 seconds between sets 4. No BFR cuffs will be used

06

What researchers measure

Primary outcomes

  1. Walking Function

    Change in walking distance measured by the Six-Minute Walk Test (6MWT) from baseline to end of intervention and 3-month follow-up visit.

    Time frame: Baseline (Visit 1), post-intervention (8 to 12 weeks), and 3-month follow-up (3MF)

  2. Quality of Life (QoL) (1)

    Change in health-related quality of life as assessed by EuroQol 5-Dimension 5-Level (EQ-5D-5L) from baseline to post-intervention and 3-month follow-up

    Time frame: Baseline (Visit 1), post-intervention (8 to 12 weeks), and 3-month follow-up (3MF)

  3. Quality of Life (QoL) (2)

    Change in depressive symptoms as assessed by Patient Health Questionnaire-9 (PHQ-9) from baseline to post-intervention and 3-month follow-up

    Time frame: Baseline (Visit 1), post-intervention (8 to 12 weeks), and 3-month follow-up (3MF)

  4. Quality of Life (QoL) (3)

    Change in self-reported walking function and symptom burden assessed by using REVASC-PAD Walking Questionnaire from baseline to post-intervention and 3-month follow-up

    Time frame: Baseline (Visit 1), post-intervention (8 to 12 weeks), and 3-month follow-up (3MF)

Secondary outcomes

  1. Claudication Onset Time (COT) during 6MWT

    Time to onset of claudication symptoms during 6MWT at baseline, post-intervention, and 3-month follow-up

    Time frame: Baseline, post-intervention (8 to 12 weeks), and 3 months post-intervention

  2. Ratings of Perceived Exertion (RPE), Dyspnea, and Claudication Pain

    Session-based self-reported symptom ratings collected at each supervised exercise session from Visit 2 to end of intervention (approximately 8 to 12 weeks). These ratings assess exercise tolerance and symptom burden during blood flow restriction training.

    Time frame: Multiple assessments from Visit 2 through end of intervention (approximately 8 to 12 weeks)

  3. Adverse Event (AE) and Serious Adverse Event (SAE) Rates

    Number and rate of adverse events and serious adverse events occurring during the study period.

    Time frame: Baseline to 3-month follow-up

  4. Enrollment, Retention, and Adherence Rates

    Rates of successful enrollment, participant retention at post-intervention and 3-month follow-up, and adherence to prescribed exercise sessions

    Time frame: Baseline to 3-month follow-up

07

Study locations

1 of 1 sites recruiting
  • University of Tennessee Medical Center
    Knoxville, Tennessee 37920, United States
    Recruiting
    • Morgan Randall, MD · Principal investigator
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2026 (actual). Primary completion is estimated for Apr 2027, 12 months after the start.

Of 261 non-industry interventional studies with no phase under Peripheral Arterial Disease, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 64. This study's planned 12 months is below that.

Counting every sponsor, half of 386 studies reached it within 31 months; a quarter within 17 and three quarters within 55.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 24, 2025
First posted
Oct 31, 2025
StartActual
Apr 27, 2026
Primary completionEst.
Apr 27, 2027
CompletionEst.
Apr 27, 2027
Last update
Nov 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date
1 update, last Nov 4, 2026
Show all 1 update
  1. Nov 4, 2026
    Minor edits only
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07223437
Lead sponsor
University of Tennessee Graduate School of Medicine
Responsible party
Sponsor
First posted
Oct 31, 2025
Start date
Apr 27, 2026
Primary completion
Apr 27, 2027 (estimated)
Completion
Apr 27, 2027 (estimated)
Last update
Nov 4, 2026

Study contacts

Tiffany Johnson, Study Coordinator
Contact
thjohnson@utmck.edu
+1865-305-4682

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion